CAPTRUST Financial Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$749K Buy
1,430
+299
+26% +$143K ﹤0.01% 1773
2025
Q4
$659K Buy
1,131
+565
+100% +$289K ﹤0.01% 1742
2025
Q3
$260K Buy
+566
New +$211K ﹤0.01% 2276
2024
Q1
Sell
-1,474
Closed -$341K 2445
2023
Q4
$341K Buy
+1,474
New +$258K ﹤0.01% 2017
2023
Q3
Sell
-3,173
Closed -$733K 2680
2023
Q2
$733K Buy
+3,173
New +$859K ﹤0.01% 1402
2022
Q3
Sell
-173
Closed -$12K 3224
2022
Q2
$12K Buy
173
+1
+0.6% +$74 ﹤0.01% 3654
2022
Q1
$17K Buy
172
+45
+35% +$3.79K ﹤0.01% 3490
2021
Q4
$11K Buy
127
+3
+2% +$246 ﹤0.01% 3661
2021
Q3
$10K Sell
124
-11
-8% -$950 ﹤0.01% 3612
2021
Q2
$13K Buy
135
+34
+34% +$4.03K ﹤0.01% 3382
2021
Q1
$12K Buy
101
+4
+4% +$466 ﹤0.01% 3338
2020
Q4
$11K Sell
97
-1,554
-94% -$190K ﹤0.01% 2524
2020
Q3
$195K Buy
1,651
+97
+6% +$10.5K ﹤0.01% 1042
2020
Q2
$174K Hold
1,554
﹤0.01% 1095
2020
Q1
$94K Buy
+1,554
New +$129K ﹤0.01% 1146
2019
Q4
Sell
-1,554
Closed -$134K 1469
2019
Q3
$134K Hold
1,554
﹤0.01% 674
2019
Q2
$163K Buy
+1,554
New +$166K 0.01% 606
2018
Q2
Sell
-41
Closed -$4K 1568
2018
Q1
$4K Sell
41
-57
-58% -$7.04K ﹤0.01% 1182
2017
Q4
$9K Buy
+98
New +$5.6K ﹤0.01% 1019

Other funds holding MDGL

CAPTRUST Financial Advisors's MDGL Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Madrigal Pharmaceuticals (MDGL) stake by 26% in Q1 2026, buying an estimated $143K and bringing the position to 1,430 shares worth $749K. The position accounts for ﹤0.01% of the portfolio, ranked #1773.

CAPTRUST Financial Advisors first reported a position in MDGL in Q4 2017 and has held it in 19 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • CAPTRUST Financial Advisors held 1,430 shares of Madrigal Pharmaceuticals worth $749K as of Q1 2026.
  • CAPTRUST Financial Advisors bought 299 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $143K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #1773 holding.
  • CAPTRUST Financial Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2017 and has held it in 19 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.